<DOC>
	<DOCNO>NCT02489773</DOCNO>
	<brief_summary>To confirm Lucica ® Glycated Albumin-L useful intermediate term ( precede 2-3 week ) monitor glycemic control patient diabetes .</brief_summary>
	<brief_title>Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study</brief_title>
	<detailed_description>In order confirm Lucica ® Glycated Albumin-L useful intermediate term ( precede 2-3 week ) monitor glycemic control patient diabetes , subject Type 1 Type 2 diabetes enrol whose HbA1c value range 7.5 % 12 % ( high ) Group 1 &lt; 7.5 % Group 2 Visit 1 , comparison glycated albumin ( GA ) glycemic control index perform 6 month 8 clinical site US . Group 1 consist 90 evaluable subject change diabetes management improve glycemic control ; therapy include oral agent , insulin , noninsulin injectable anti-diabetic medication . Group 2 consist 40 evaluable subject already stable diabetic management program , change treatment last 3 month plan make change study period .</detailed_description>
	<criteria>Subjects may include study meet follow criterion : 1 . Male female subject 18 year age old 2 . Subjects Type 1 Type 2 diabetes ( enrolled approximate ratio 1:1 , respectively ) 3 . Subjects HbA1c value within range 7.5 % 12 % ( high ) Group 1 &lt; 7.5 % Group 2 Note : The study investigator primary physician must plan institute , must process instituting , therapy improve glycemic control subject Group 1 ; therapy include oral agent , insulin , noninsulin injectable antidiabetic medication . 4 . Willingness complete protocol requirement , include use SMBG attendance schedule study visit ; select CGM monitoring , willingness follow additional requirement use CGM device model provide study 5 . Satisfactory completion home SMBG measurement screen period study prior enrollment Visit 2 Subjects exclude study meet follow criterion : 1 . Any clinically significant disease , determine investigator , would interfere study evaluation include limit follow current historical conditions/procedures ( selfreported subject ) : 1 . Endstage renal disease 2 . Chronic kidney disease Stage 3 great 3 . Liver cirrhosis 4 . Uncontrolled untreated thyroid disease 5 . Any acute chronic condition , opinion investigator , may significantly influence albumin glucose metabolism ( Note : routine iron deficiency abnormal hemoglobin variant exclusion ) 2 . History within last 6 month blood transfusion 3 . Any condition factor , opinion investigator , would complicate compromise study wellbeing subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lucica</keyword>
	<keyword>glycated albumin</keyword>
	<keyword>GA</keyword>
	<keyword>fructosamine</keyword>
</DOC>